Philadelphia 2022 Q3 News Recap – Cellicon Valley Continues to Showcase Strengths

Published on : Published by : Alex Keown

According to the recent Life Sciences Research Outlook & Cluster Rankings report from JLL, the Greater Philadelphia region has advanced four positions in the Life Sciences Cluster Composition Matrix, which measures how each market stacks up in terms of human and physical capital. The regional improvement was due to increased and steady funding supporting the specialization of cell and gene therapy research being conducted in the area, which comes as no surprise as these therapies continue to become increasingly important options in disease treatment.

Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure

Published on : Published by : BioBuzz Media

Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure WARRINGTON, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) — Windtree [….]

Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement

Published on : Published by : BioBuzz Media

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today announced it has entered into a global licensing agreement with Lee’s Pharmaceutical (HK) Limited, (Lee’s) and its affiliate Zhaoke Pharmaceutical (Hefei) Co. Ltd., (Zhaoke) for the development and commercialization of Windtree’s acute pulmonary pipeline treatments KL4 surfactant and drug/device combination, AEROSURF®, for the treatment of preterm infants with respiratory distress syndrome (RDS) and other potential applications. RDS often occurs in preterm infants when the lung is not fully developed with natural lung surfactant and may require surfactant therapy to sustain life.

Windtree Therapeutics Leverages Heart Failure Asset Istaroxime in Multiple Indications

Published on : Published by : Alex Keown

Windtree Therapeutics Chief Executive Officer Craig Fraser called 2020 a transformative and productive year for the Bucks County company focused on the development of life-saving therapeutics for acute cardiovascular and pulmonary disorders. Despite cardiovascular disease being the number-one cause of global death, Fraser said few companies are pouring their resources into addressing the disease, especially when compared to oncology research. Windtree’s lead clinical program istaroxime is a novel therapeutic aimed at heart failure, the number one reason for hospitalization in the United States.